Selected Publications from 2022

Publications

Targeting progesterone reduces epigenetic and genetic cancer surrogates in normal breast tissue
Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, Papaikonomou K, Jones L, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan, Boggavarapu SNR, Lalitkumar PG, Howell SJ, Risques RA, Rådestad AF, Dubeau L, Gemzell-Danielsson K and Widschwendter M*.
Genome Medicine, 14 (1), 1-18.  2022   
 
Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.
Breast Cancer Association Consortium, Mavaddat N, Dorling L, Carvalho S, Allen J, González-Neira A, Keeman R, Bolla MK, Dennis J, Wang Q, Ahearn TU, Andrulis IL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Briceno I, Brüning T, Camp NJ, Campbell A, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Christiansen H, Czene K, Dörk T, Eriksson M, Evans DG.....Howell A et al.
JAMA Oncol. 2022 Jan 27. doi: 10.1001/jamaoncol.2021.6744.   2022   
 
Combined Peri-operative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer can Identifies Early Responders: Randomized UK EPHOS-B Trial Long term results
Bundred N, Port N, Brunt AM, Cramer A, Hanby A, Shaaban A, Rakha EA, Armstrong A, Cutress RI, Dodwell D et al.
Clin Cancer Research DOI: 10.1158/1078-0432.CCR-21-3177  2022   
 
The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?
Evans DG, van Veen EM, Byers H, Roberts E, Howell A, Howell SJ, Harkness EF, Brentnall A, Cuzick J, Newman WG
Int J Cancer. 2022 Jan 1;150(1):73-79. doi: 10.1002/ijc.33782.  2022   
 
Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk and a gene panel
Evans, D. G., Van Veen, E., Harkness, E., Brentnall, A., Astley, S., Byers, H., Woodward, E., Sampson, S., Southworth, J., Howell, S., Maxwell, A., Newman, W., Cuzick, J. & Howell, T.
Genetics in Medicine  2022  14 Mar 2022, (Accepted/In press)  
 
Fibroblast Growth Factor Receptor signalling dysregulation and targeting in breast cancer.
Francavilla C and O’Brien C
Open Biology. Review. Feb;12(2):210373. doi: 10.1098/rsob.210373. Epub 2022 Feb 23. Free PMC article  2022   
 
Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer
Harvie M, Pegington M, Howell SJ, Bundred N, Foden P, Adams J, Graves L, Greystoke A, Mattson MP, Cutler RG, Williamson J, Livingstone K, McMullen D, Sellers K, Lombardelli C, Cooper G, McDiarmid S, Howell A.
Br J Cancer. 2022 May;126(8):1157-1167. doi: 10.1038/s41416-021-01650-0. Epub 2021 Dec 15.PMID: 34912072 Free PMC article. Clinical Trial.  2022   
 
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH.
Lancet Oncol. 2022 Jul;23(7):851-864.  2022   
 
Mitochondrial dynamics regulate genome stability via control of caspase-dependent DNA damage
Kai Cao, Joel S Riley, Rosalie Heilig, Alfredo E Montes-Gómez, Esmee Vringer, Kevin Berthenet, Catherine Cloix, Yassmin Elmasry, David G Spiller, Gabriel Ichim, Kirsteen J Campbell, Andrew P Gilmore, and Stephen W G Tait
Developmental Cell. 10.1016/j.devcel.2022.03.019  2022   
 
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Pellegrino B, Herencia A, Llop-Guevara A, Pedretti F, Moles A, Viaplana C, Villacampa G, Guzmán M, Rodríguez O, Grueso J, Jimenez J, Forment JV, O’Connor MJ, Cairo S, Zhou Y, Musolino A, Caldas C, Clarke RB, Nuciforo P, Díez O, Serres X, Peg V, Espinosa M, Macarulla T, Oaknin A, Mateo J, Bellet M, Oliveira M, Saura C, Gutiérrez-Enríquez S, Balmaña J and Serra V
Cancer Res., 82(8):1646-1657.  2022   
 
BROWSE: A multicentre comparison of nine year outcomes in acellular dermal matrix based and complete submuscular implant-based immediate breast reconstruction-aesthetics, capsular contracture and patient reported outcomes
Wilson RL, Kirwan CC, O'Donoghue JM, Linforth RA, Johnson RK, Harvey JR
Eur J Surg Oncol  2022  Jan;48(1):73-81. doi: 10.1016/j.ejso.2021.10.026. Epub 2021 Nov 6. PMID: 34836730. 
 
Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition
Zhang J, Pearson AJ, Sabherwal N, Telfer BA, Ali N, Kan K, Xu Q, Zhang W, Chen F, Li S, Wang J, Gray NS, Risa-Ebrí B, Finegan KG, Cross MJ, Giurisato E, Whitmarsh AJ, Tournier C
Cancer Res Commun 2,131-145  2022   
 


Seminars

Date:  28 November 2024, 00:00
Speaker:  Charlotte Coles
From:  University of Cambridge
Title:  The Lancet Breast Cancer Commission
Host:  MBC Symposium
 
Date:  28 November 2024, 00:00
Speaker:  Therese Sørlie
From:  University of Oslo, Norway
Title:  Breast cancer progression in humans and mouse models
Host:  MBC Symposium
 
Date:  28 November 2024, 00:00
Speaker:  Brian Booth
From:  Clemson University, South Carolina, USA
Title:  Phenotypic switching in mammary gland and breast cancer
Host:  MBC Symposium
 
Date:  28 November 2024, 00:00
Speaker:  Momo Bentires-Alj
From:  University of Basel, Switzerland
Title:  Breast Cancer Metastasis: Act Locally, Think Globally
Host:  MBC Symposium